Therapeutic Area

COPD

Therapeutic area intelligence for COPD with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 2

Companies

AstraZeneca →

Pfizer →

Assets

Respiratory →

Spiriva →

Tozorakimab →

Recent signals(4)

ClinicalJune 18, 2026

Study Reveals Mucus-Plug Dynamics in COPD Patients and Ex-Smokers

In a study of ex-smokers, mucus-plugs persisted in one-third of patients with COPD, while new plugs developed in others, indicating complex dynamics.

ClinicalJune 16, 2026

Tozorakimab Shows Positive Phase III Results in COPD, Reducing Exacerbations

Tozorakimab met its primary endpoint in the Phase III MIRANDA trial, showing significant reduction in COPD exacerbations.

ClinicalJune 2, 2026

Tozorakimab achieves primary endpoints in Phase III trials for COPD

Tozorakimab met primary endpoints in both OBERON and TITANIA Phase III trials, showing significant reductions in COPD exacerbations.

ClinicalJune 1, 2026

Study on NMES for Functional Recovery in COPD and Pneumonia Patients

A clinical trial is investigating the feasibility of neuromuscular electrical stimulation (NMES) to improve recovery in older adults with AECOPD and community-acquired pneumonia.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

COPD →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.